Point72 Europe’s Oric Pharmaceuticals ORIC Stock Holding History

Point72 Europe’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.36K	Buy	+113	New	+$1.19K	﹤0.01%	684

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Point72 Europe's ORIC Position: Q3 2025 in Review

Point72 Europe opened a new position in Oric Pharmaceuticals (ORIC) in Q3 2025: 113 shares worth $1.36K. The stake represents ﹤0.01% of the portfolio and ranks #684 among its holdings.

152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

Point72 Europe held 113 shares of Oric Pharmaceuticals worth $1.36K as of Q3 2025.
Oric Pharmaceuticals was a new Point72 Europe position in Q3 2025.
Oric Pharmaceuticals made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #684 holding.
152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.